Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Louapre

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Revue Neurologique|May 12, 2026
New tools to shape the future of MS and related disordersC Louapre
Revue Neurologique|May 23, 2018
Conventional and advanced MRI in multiple sclerosisC Louapre
Revue Neurologique|February 12, 2022
Genetics and familial distribution of multiple sclerosis: A reviewA Balcerac, C Louapre
Revue Neurologique|April 12, 2026
Remyelination and neuroprotection translational trials: Lessons from optic neuritisC Louapre, Y Beigneux, F Maestri, et al.
Revue Neurologique|April 22, 2020
Headache and multifocal white matter lesions: Radiologically Isolated Syndrome or CADASIL?J Mazoyer, C Louapre, N Shor, et al.
Multiple Sclerosis and Related Disorders|January 12, 2020
Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic reviewL A Visser, C Louapre, C A Uyl-de Groot, et al.
Revue Neurologique|May 5, 2020
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrumC Louapre, E Maillart, T Roux, et al.
Revue Neurologique|March 27, 2019
Impact of an adaptive program for cognitive and emotional deficits (ADACOG program) in multiple sclerosis patients with cognitive impairmentsF Pineau, J Socha, J-C Corvol, et al.
Revue Neurologique|August 26, 2023
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivationS Gassama, A Garmendia, F X Lejeune, et al.
Revue Neurologique|November 14, 2025
Artificial intelligence in presymptomatic neurological diseases: Bridging normal variation and prodromal signaturesT Soulier, N Burgos, R Hassanaly, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Revue Neurologique|May 12, 2026
New tools to shape the future of MS and related disordersC Louapre
Revue Neurologique|May 23, 2018
Conventional and advanced MRI in multiple sclerosisC Louapre
Revue Neurologique|February 12, 2022
Genetics and familial distribution of multiple sclerosis: A reviewA Balcerac, C Louapre
Revue Neurologique|April 12, 2026
Remyelination and neuroprotection translational trials: Lessons from optic neuritisC Louapre, Y Beigneux, F Maestri, et al.
Revue Neurologique|April 22, 2020
Headache and multifocal white matter lesions: Radiologically Isolated Syndrome or CADASIL?J Mazoyer, C Louapre, N Shor, et al.
Multiple Sclerosis and Related Disorders|January 12, 2020
Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic reviewL A Visser, C Louapre, C A Uyl-de Groot, et al.
Revue Neurologique|May 5, 2020
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrumC Louapre, E Maillart, T Roux, et al.
Revue Neurologique|March 27, 2019
Impact of an adaptive program for cognitive and emotional deficits (ADACOG program) in multiple sclerosis patients with cognitive impairmentsF Pineau, J Socha, J-C Corvol, et al.
Revue Neurologique|August 26, 2023
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivationS Gassama, A Garmendia, F X Lejeune, et al.
Revue Neurologique|November 14, 2025
Artificial intelligence in presymptomatic neurological diseases: Bridging normal variation and prodromal signaturesT Soulier, N Burgos, R Hassanaly, et al.
Pageof 2